通过下一代测序进行微小残留病评估。是能更好地洞察未来的工具吗？ - Suppr

Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

作者信息

Balduzzi A

机构信息

Clinica Pediatrica Università degli Studi di Milano Bicocca, Monza (MB), Italy.

出版信息

Bone Marrow Transplant. 2017 Jul;52(7):952-954. doi: 10.1038/bmt.2017.104. Epub 2017 Jun 5.

DOI:10.1038/bmt.2017.104

PMID:28581473

Abstract

摘要

相似文献

Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Bone Marrow Transplant. 2017 Jul;52(7):952-954. doi: 10.1038/bmt.2017.104. Epub 2017 Jun 5.

Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.

Br J Haematol. 2017 Jan;176(2):318-321. doi: 10.1111/bjh.13948. Epub 2016 Jan 29.

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon Rinsho. 2016 Jul;74 Suppl 5:565-9.

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.

Eur J Haematol. 2017 Jan;98(1):26-37. doi: 10.1111/ejh.12780. Epub 2016 Jun 8.

Next-generation sequencing for measuring minimal residual disease in AML.

Nat Rev Clin Oncol. 2018 Aug;15(8):473-474. doi: 10.1038/s41571-018-0040-0.

Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?

J Clin Oncol. 2024 Aug 10;42(23):2736-2740. doi: 10.1200/JCO.23.02301. Epub 2024 May 16.

Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.

Am Soc Clin Oncol Educ Book. 2016;35:e425-30. doi: 10.1200/EDBK_159088.

Standardisation of minimal residual disease in multiple myeloma.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12732. Epub 2017 Jul 3.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.

Ann Lab Med. 2017 Jul;37(4):331-335. doi: 10.3343/alm.2017.37.4.331.

引用本文的文献

[Clinical application of minimal residual disease detection in childhood acute leukemia].

Zhongguo Dang Dai Er Ke Za Zhi. 2018 May;20(5):416-420. doi: 10.7499/j.issn.1008-8830.2018.05.015.

本文引用的文献

Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Bone Marrow Transplant. 2017 Jul;52(7):962-968. doi: 10.1038/bmt.2017.16. Epub 2017 Feb 27.

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Blood. 2017 Apr 6;129(14):1913-1918. doi: 10.1182/blood-2016-12-725804. Epub 2017 Feb 6.

The Value of Minimal Residual Disease (and Diamonds).

Biol Blood Marrow Transplant. 2017 Jan;23(1):3-5. doi: 10.1016/j.bbmt.2016.11.012. Epub 2016 Nov 16.

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.

Biol Blood Marrow Transplant. 2017 Jan;23(1):87-95. doi: 10.1016/j.bbmt.2016.10.006. Epub 2016 Oct 11.

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.

Blood. 2015 Aug 20;126(8):1045-7. doi: 10.1182/blood-2015-07-655159.

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

Bone Marrow Transplant. 2015 Sep;50(9):1173-9. doi: 10.1038/bmt.2015.103. Epub 2015 May 11.

Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.

J Clin Oncol. 2015 Apr 10;33(11):1275-84. doi: 10.1200/JCO.2014.58.4631. Epub 2015 Jan 20.

Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.

Br J Haematol. 2015 Apr;169(2):249-61. doi: 10.1111/bjh.13272. Epub 2014 Dec 19.

Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.

Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14.

Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes?

Biol Blood Marrow Transplant. 2014 Oct;20(10):1461-2. doi: 10.1016/j.bbmt.2014.07.026. Epub 2014 Jul 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献